Optimal Health Insider- Edition 8

March 8, 2017

 

TACT-2-logo

 

U.P. Holistic Medicine to Participate in
National Institutes of Health
TACT2 Research Trial

Second study will focus on benefits of
removing toxic metal pollutants in patients
with diabetes and a prior heart attack

FOR IMMEDIATE RELEASE March 8, 2017 (Chocolay Township, MI): U.P. Holistic Medicine has been
named a participating clinical site for the second Trial to Assess Chelation Therapy (TACT2).
TACT2 will examine the use of intravenous chelation treatments in combination with oral
vitamins in diabetic patients with a prior heart attack to determine if they reduce recurrent heart
episodes, such as heart attacks, stroke, death, and others, by removing toxins from the blood.
Funding for TACT2 was announced in September of 2016 when The National Center for
Complementary and Integrative Health (NCCIH) of the National Institutes of Health (NIH)
awarded $37M to initiate the trial. The trial is also co-funded by the National Heart, Lung and
Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases and the
National Institute of Environmental Health Sciences.
Chelation is a process by which a medication, such as edetate disodium (Na2EDTA), can “grab” and
remove toxic metal pollutants – like lead or cadmium – which are present in most individuals.
TACT2 follows up on the positive results of TACT, an NIH-sponsored multicenter, double-blind
safety and efficacy study, which took place from 2002- 2012 and was conducted in 134 sites across
the United States and Canada. During TACT, 1,708 heart attack patients were randomly assigned to
receive 40 infusions of an edetate disodium-based chelation solution or a placebo (inactive)
infusion. Patients also received an oral vitamin and mineral regimen, or an oral placebo.
TACT demonstrated an 18% reduction in recurrent heart events by chelation in patients who already
had sustained a heart attack. Recurrent heart events measured in the study were death, heart
attack, stroke, heart bypass or stent, and hospitalization for angina (chest pains). In 633 diabetic
patients, there was an even larger benefit with a 41% reduction in recurrent heart events and a 43%
reduction in deaths. Based on these results, the Mount Sinai and Duke scientists who conducted
the trial felt that a repeat study was important to carry out.
TACT2 will narrow its focus to the group with the greatest benefit in the original study – diabetic
patients 50- years of age or older who have survived a prior heart attack.
-more-
The original TACT clinical results were published in the Journal of the American Medical
Association in 2013, Circulation: Quality and Outcomes in 2014, and the American Heart Journal
in 2014.
“This is a wonderful opportunity for U.P. residents to participate in clinical research and help
answer an important question,” said Scott Doughty, M.D., founder of U.P. Holistic Medicine in
Chocolay Township. “The original TACT results showed chelation benefits people with heart
disease and diabetes. Now, a closer look at chelation’s effects on those individuals (with
diabetes and past heart attack) will fine-tune our understanding of environmental impacts on
heart health, and potentially enhance both the length and quality of patients’ lives. That’s a
game-changer!”
“If TACT2 is positive, it will forever change the way we treat heart attack patients and view toxic
metals in the environment,” said Gervasio Lamas, M.D., study chairman and chief of the
Columbia Division of Cardiology at Mount Sinai Medical Center in Miami Beach, Florida.
“Therefore, with NIH support and in collaboration with the Duke Clinical Research Institute,
Columbia University, New York University, Mount Sinai (NYC), and hundreds of physicians and
nurses throughout the U.S. and Canada, we are moving forward with TACT2.”
Although not approved by the Food and Drug Administration for treating heart disease, some
practitioners have used chelation therapy for nearly 60 years in the absence of clinical trial data
supporting its use. Because of the lack of data, it has generally been believed by conventional
medical practitioners and cardiologists to be without value, although TACT results suggest
otherwise. A definitive answer on chelation therapy in diabetic patients that will be embraced by the
cardiology community will require positive results from TACT2.
U.P. Holistic Medicine is currently recruiting patients for participation in the study. Candidates must
be 50 years of age or older, have diabetes and experienced a prior heart attack. Patients interested
in participating may contact the study team through www.tact2.org, or by calling 906-249-3600 to
speak with Dr. Doughty or his staff. More information about U.P. Holistic Medicine can be found at
upholisticmedicine.com.
This work is supported by the following grants: R01AT009273 and UH3AT009149. Oral vitamins
are provided by Xymogen (Orlando FL).
# # #